Chapters Transcript Video Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. A study of an oval HIF2 uh inhibitor by the name Catatifan in previously treated metastatic uh clear cell uh renal cell cancer. Overall, uh, we found that the treatment um was relatively well tolerated with side effects being manageable, including mostly anemia. Uh, as the most common side effect. Um, all grade hypoxia were around 10 to 15%. All grade anemia or grade 3 anemia where 36%, and most important was the clinical activity in the dose expansion dealing with renal cell cancer, which was between Um, depending on the, on the dose, 50 mg BID or 50 mg UD between 20 and 30% with the disease control rate over 80%. The median progression free survival was not reached in, um, uh, both arms. Uh, so overall, um, Um, again, uh, the drug was well tolerated, no DLTs, NTD was not, uh, reach, and, um, in both 50 mg once a day and 50 mg twice a day, we saw durable clinical, uh, activity. Uh, at some point, an unconfirmed response rate up to 34%. In the 50 mg twice a day, the 100 mg a day uh cohort. And uh this um has led to um Peak one, which is a phase three trial evaluating the combination of the HEP2 inhibitor Castadian plus cabozantinib versus cabozantinib following PD1 uh therapy. Published February 26, 2025 Created by Related Presenters Toni Choueiri, MD Medical Oncology View Full Profile
